Clinical trial

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy…

NCT00347672 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00347672
Title Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Official title Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Johns Hopkins Bloomberg School of Public Health
Status Completed
Phase Phase 1
Study type Interventional
Conditions Influenza, Virus Diseases
Intervention type Biological
Interventions H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Enrollment 42
Start date Jun 1, 2006
Primary completion Jul 1, 2007
Completion Jul 1, 2007
First posted Jul 4, 2006
Last update posted Jan 21, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies